Publications by authors named "O Kawaguchi"

Article Synopsis
  • Sutimlimab, a new treatment approved in Japan for cold agglutinin disease (CAD), showed positive safety and efficacy results in Japanese patients from a global phase 3 clinical trial and an open-label extension study.
  • In the studies, most patients were female with a median age of 70, and a notable percentage experienced mild adverse effects like injection site reactions and infections.
  • Overall, sutimlimab was well tolerated over an average treatment duration of nearly 3.8 years, with improvements in hemoglobin and bilirubin levels observed during treatment, and no new safety issues arose during retreatment.
View Article and Find Full Text PDF

Coronary artery spasm after coronary artery bypass grafting is a rare but life-threatening condition. Herein, we report the case of a 77-year-old man who received off-pump coronary artery bypass grafting. An hour after surgery, there was a sudden hemodynamic compromise due to coronary artery spasm, prompting emergent coronary angiography with extracorporeal membrane oxygenation support.

View Article and Find Full Text PDF

In this report, we present a case in which we successfully performed two-stage hybrid repair of heart surgery and endoscopic treatment with over-the-scope-clip system for atrio-esophageal fistula after catheter based ablation.

View Article and Find Full Text PDF

Introduction And Importance: Primary cardiac angiosarcoma is extremely rare, and its prognosis remains poor, with a mean life expectancy of only a few months. Here, we report a case of primary cardiac angiosarcoma.

Case Presentation: A 49-year-old Japanese woman with a month-long history of dyspnea was admitted to our hospital for pericardial effusion.

View Article and Find Full Text PDF

Angiogenesis is a hallmark of cancer development. This study sought to determine the recommended dose of aflibercept, a recombinant fusion protein targeting VEGF-A, VEGF-B and placental growth factor (PlGF), combined with docetaxel in Japanese patients with advanced solid malignancies. This phase I study was planned to include 12 patients following a 3 + 3 algorithm to determine the maximum tolerated dose of aflibercept combined with docetaxel in patients with metastatic or unresectable solid tumors (trial registration: NCT00545246).

View Article and Find Full Text PDF